{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:22:58Z","timestamp":1787977378735,"version":"build-2784847793"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Hypothesis<\/jats:title>\n                  <jats:p>In response to Health Canada\u2019s March 2020 directive, patients on clozapine for over 12 months were allowed to extend hematological testing intervals from 4 to 8 weeks during the COVID-19 pandemic. We hypothesized that this change would not affect the timely detection of hematological abnormalities in patients with severe mental illness.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study Design<\/jats:title>\n                  <jats:p>A chart review was conducted of patients at the Royal Ottawa who were prescribed clozapine from March 2019 to March 2021. We analyzed clinical and hematological data from electronic health records and Clozaril Support and Assistance Network database to compare occurrences of hematological abnormalities [leukopenia (white blood cell count &amp;lt;3.5\u2005\u00d7\u2005109\/L) and agranulocytosis (absolute neutrophil count &amp;lt;0.5\u2005\u00d7\u2005109\/L)] from March 17, 2020 to March 16, 2021, between standard and extended monitoring protocols using binomial logistic and zero-inflated negative binomial regressions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study Results<\/jats:title>\n                  <jats:p>Of 621 patients, 196 were on extended blood monitoring, and 425 followed standard blood monitoring. Clozapine dose did not differ between groups (standard: 370\u2005\u00b1\u2005201 mg; extended: 352\u2005\u00b1\u2005172 mg; P\u2005=\u2005.14, ds\u2005=\u20050.10). Clozapine treatment duration up to March 2021 was 12.6\u2005\u00b1\u20058.3 years, with the extended group (10\u2005\u00b1\u20057.9 years) having a significantly (P\u2005&amp;lt;\u2005.01, ds\u2005=\u20050.50) shorter duration than the standard (14\u2005\u00b1\u20058.2 years). Extended monitoring did not significantly impact likelihood of detecting hematological abnormalities (OR\u2005=\u20050.83, 95% CI [0.58,1.41], P\u2005=\u2005.55) after controlling for age, sex, total bloodwork, and other psychotropics associated with neutrophil counts (ie, valproate, olanzapine). No patient on the extended regimen developed agranulocytosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Reducing blood monitoring frequency in patients on clozapine for more than 12 months did not compromise detection of hematological abnormalities.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/schbul\/sbae113","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T05:56:29Z","timestamp":1718862989000},"page":"493-500","source":"Crossref","is-referenced-by-count":7,"title":["Evaluating Reduced Blood Monitoring Frequency and the Detection of Hematological Abnormalities in Clozapine-Treated Patients With Schizophrenia: A Chart Review Study From the COVID-19 Pandemic"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9873-6790","authenticated-orcid":false,"given":"Helen","family":"Thai","sequence":"first","affiliation":[{"name":"Department of Psychology, McGill University , Montreal, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1222-221X","authenticated-orcid":false,"given":"Nicholas","family":"Preobrazenski","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Psychiatry, University of Ottawa , Ottawa, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0843-5879","authenticated-orcid":false,"given":"TiChen","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Integrated Schizophrenia Recovery Program, Royal Ottawa Mental Health Centre , Ottawa, Ontario ,","place":["Canada"]},{"name":"Faculty of Medicine, Department of Psychiatry, University of Ottawa , Ottawa, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Robertson","sequence":"additional","affiliation":[{"name":"Integrated Schizophrenia Recovery Program, Royal Ottawa Mental Health Centre , Ottawa, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3932-1780","authenticated-orcid":false,"given":"Olabisi","family":"Owoeye","sequence":"additional","affiliation":[{"name":"Integrated Schizophrenia Recovery Program, Royal Ottawa Mental Health Centre , Ottawa, Ontario ,","place":["Canada"]},{"name":"Faculty of Medicine, Department of Psychiatry, University of Ottawa , Ottawa, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"issue":"5","key":"2025031503074939900_CIT0001","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis","volume":"209","author":"Siskind","year":"2016","journal-title":"Br J Psychiatry."},{"key":"2025031503074939900_CIT0002","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","article-title":"Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia","volume":"20","author":"Horacek","year":"2006","journal-title":"CNS Drugs."},{"issue":"1","key":"2025031503074939900_CIT0003","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/schbul\/sbq042","article-title":"Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons","volume":"38","author":"Rummel-Kluge","year":"2012","journal-title":"Schizophr Bull."},{"issue":"5","key":"2025031503074939900_CIT0004","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1176\/ps.2008.59.5.547","article-title":"Utilization and costs of antipsychotic agents: a Canadian population-based study, 1996\u20132006","volume":"59","author":"Alessi-Severini","year":"2008","journal-title":"Psychiatr Serv."},{"issue":"4","key":"2025031503074939900_CIT0005","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1192\/bjp.169.4.483","article-title":"Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland","volume":"169","author":"Atkin","year":"1996","journal-title":"Br J Psychiatry."},{"issue":"1","key":"2025031503074939900_CIT0006","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s12888-016-1167-0","article-title":"Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland","volume":"16","author":"Ingimarsson","year":"2016","journal-title":"BMC Psychiatry."},{"issue":"5","key":"2025031503074939900_CIT0007","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0004867419833166","article-title":"A meta-analysis of controlled studies comparing the association between clozapine and other antipsychotic medications and the development of neutropenia","volume":"53","author":"Myles","year":"2019","journal-title":"Aust N Z J Psychiatry."},{"issue":"2","key":"2025031503074939900_CIT0008","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/acps.12898","article-title":"Meta-analysis examining the epidemiology of clozapine-associated neutropenia","volume":"138","author":"Myles","year":"2018","journal-title":"Acta Psychiatr Scand."},{"key":"2025031503074939900_CIT0009","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1017\/S204579602200066X","article-title":"Clozapine haematological monitoring for neutropenia: a global perspective","volume":"31","author":"Oloyede","year":"2022","journal-title":"Epidemiol Psychiatr Sci."},{"issue":"1","key":"2025031503074939900_CIT0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2215-0366(23)00343-7","article-title":"Evaluating the epidemiology of clozapine-associated neutropenia among people on clozapine across Australia and Aotearoa New Zealand: a retrospective cohort study","volume":"11","author":"Northwood","year":"2024","journal-title":"Lancet Psychiatry."},{"issue":"7","key":"2025031503074939900_CIT0011","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1177\/070674379203700704","article-title":"Clozapine in the treatment of refractory schizophrenia: Canadian policies and clinical guidelines","volume":"37","author":"Collins","year":"1992","journal-title":"Can J Psychiatry."},{"issue":"11","key":"2025031503074939900_CIT0012","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1007\/s00277-020-04215-y","article-title":"Clozapine-induced agranulocytosis","volume":"99","author":"Mijovic","year":"2020","journal-title":"Ann Hematol."},{"issue":"4","key":"2025031503074939900_CIT0013","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1345\/aph.1G396","article-title":"Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring","volume":"40","author":"Schulte","year":"2006","journal-title":"Ann Pharmacother."},{"issue":"1","key":"2025031503074939900_CIT0014","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41537-023-00353-0","article-title":"What are the barriers and facilitators of clozapine use in early psychosis? A survey of UK early intervention clinicians","volume":"9","author":"Oloyede","year":"2023","journal-title":"Schizophrenia (Heidelb)."},{"key":"2025031503074939900_CIT0015","volume-title":"CLOZARIL\u00ae (Clozapine) \u2013 COVID-19, Update Health Canada Guidance","author":"CSAN\u00ae Clozaril Support and Assistance Network","year":"2022"},{"key":"2025031503074939900_CIT0016","volume-title":"Hematological Quick Reference Chart","author":"Clozaril Support and Assistance Network","year":"2022"},{"issue":"1","key":"2025031503074939900_CIT0017","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12888-023-04659-2","article-title":"Valproate-related neutropenia and lithium-related leukocytosis in patients treated with clozapine: a retrospective cohort study","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Psychiatry."},{"issue":"2","key":"2025031503074939900_CIT0018","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/01.jcp.0000117428.05703.16","article-title":"Olanzapine-induced neutropenia: mechanism and treatment","volume":"24","author":"Duggal","year":"2004","journal-title":"J Clin Psychopharmacol."},{"issue":"3","key":"2025031503074939900_CIT0019","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1381\/096089206776116453","article-title":"Obesity and the white blood cell count: changes with sustained weight loss","volume":"16","author":"Dixon","year":"2006","journal-title":"Obes Surg."},{"issue":"1","key":"2025031503074939900_CIT0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12902-015-0002-9","article-title":"Relationship between neutrophil-lymphocyte ratio and insulin resistance in newly diagnosed type 2 diabetes mellitus patients","volume":"15","author":"Lou","year":"2015","journal-title":"BMC Endocr Disord."},{"issue":"2","key":"2025031503074939900_CIT0021","first-page":"209","article-title":"R-squared measures for count data regression models with applications to health-care utilization","volume":"14","author":"Cameron","year":"1996","journal-title":"J Bus Econ Stat."},{"issue":"4","key":"2025031503074939900_CIT0022","first-page":"200061","article-title":"Consensus statement on the use of clozapine during the COVID-19 pandemic","volume":"45","author":"Siskind","year":"2020","journal-title":"J Psychiatry Neurosci."},{"issue":"2","key":"2025031503074939900_CIT0023","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/npr2.12166","article-title":"No adverse events were observed in clozapine-treated patients on extended hematologic monitoring intervals during the coronavirus pandemic in four psychiatric centers in Japan","volume":"41","author":"Hata","year":"2021","journal-title":"Neuropsychopharmacol Rep."},{"issue":"2","key":"2025031503074939900_CIT0024","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.2023.44","article-title":"Clinical impact of reducing the frequency of clozapine monitoring: controlled mirror-image cohort study","volume":"223","author":"Oloyede","year":"2023","journal-title":"Br J Psychiatry."},{"issue":"6","key":"2025031503074939900_CIT0025","doi-asserted-by":"crossref","first-page":"e12414","DOI":"10.1111\/cob.12414","article-title":"COVID-19: impact of obesity and diabetes on disease severity","volume":"10","author":"Al-Sabah","year":"2020","journal-title":"Clin Obes."},{"issue":"1","key":"2025031503074939900_CIT0026","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cmi.2021.09.010","article-title":"Obesity, diabetes, hypertension and severe outcomes among inpatients with coronavirus disease 2019: a nationwide study","volume":"28","author":"Bailly","year":"2022","journal-title":"Clin Microbiol Infect."}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/51\/2\/493\/58497463\/sbae113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/51\/2\/493\/58497463\/sbae113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T03:08:05Z","timestamp":1742008085000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/51\/2\/493\/7710508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,7,10]]},"published-print":{"date-parts":[[2025,3,14]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbae113","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,7,10]]}}}